ANIX
HealthcareAnixa Biosciences, Inc.
$3.18
+$0.02 (+0.63%)
Jan 5, 2026
Price History (1Y)
Analysis
Anixa Biosciences, Inc. is a healthcare company operating within the biotechnology industry. The company's market capitalization stands at $104.68 million, indicating its relatively small scale compared to larger industry players. The company has reported significant net income losses in recent periods, with a net loss of $11,115,000 (TTM). This is accompanied by negative profitability margins, including gross margin, operating margin, and profit margin all being 0.0%. The returns on equity (-62.2%) and return on assets (-36.9%) are also negative, indicating substantial losses in these areas. The balance sheet shows a relatively low level of debt ($213,000) compared to cash reserves ($16.03 million), resulting in a debt-to-equity ratio of 1.38. The company's valuation metrics include a forward price-to-earnings ratio of -8.37 and a price-to-book ratio of 6.28. The beta value is 0.50, indicating a relatively stable stock performance compared to the broader market.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Anixa Biosciences, Inc.
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs include the development of a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company's vaccine programs include the development of a vaccine against breast cancer, initially focused on triple negative breast cancer (TNBC), the most lethal form of breast cancer; and the development of a vaccine against ovarian cancer, as well as a vaccine discovery program to develop additional cancer vaccines to address intractable cancers, including high incidence malignancies in lung, colon, and prostate. Its vaccine technologies focus on the discovery of additional retired proteins that may be associated with other forms of cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
Visit website →Key Statistics
- Market Cap
- $104.68M
- P/E Ratio
- N/A
- 52-Week High
- $5.46
- 52-Week Low
- $2.07
- Avg Volume
- 335.54K
- Beta
- 0.50
Company Info
- Industry
- Biotechnology
- Exchange
- NCM
- Country
- United States
- Employees
- 5